Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) shares gapped down before the market opened on Thursday. The stock had previously closed at $7.65, but opened at $6.70. Oxford BioMedica shares last traded at $6.70, with a volume of 7,462 shares traded.
Analysts Set New Price Targets
Separately, Zacks Research upgraded Oxford BioMedica to a “hold” rating in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Hold rating. According to MarketBeat.com, the company presently has an average rating of “Hold”.
Check Out Our Latest Research Report on OXBDF
Oxford BioMedica Trading Down 12.4%
About Oxford BioMedica
Oxford BioMedica plc is a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company works with biotechnology and pharmaceutical customers to develop, manufacture and test viral vectors and other biological materials used in advanced therapies.
Its capabilities include process and analytical development, clinical and commercial manufacturing, quality control, regulatory support and technology transfer. Oxford BioMedica has particular expertise in lentiviral vectors, which are used to deliver genetic material into cells, and also provides services involving adeno-associated virus and other viral-vector platforms.
Founded in 1995 and headquartered in Oxford, England, the company serves customers internationally across the pharmaceutical and biotechnology industries.
Featured Stories
- Five stocks we like better than Oxford BioMedica
- Synopsys Signals Confidence With $1B Accelerated Buyback, Analysts Raise Targets
- Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But Up
- Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?
- Failed Breakout in Tech? 3 Sectors Leading the Market Rotation
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
